The Drug Enforcement Administration has moved to classify several psychedelic compounds as Schedule I substances just days after the Food and Drug Administration held a landmark public hearing on accelerating psychedelic therapy development.
The conflicting federal moves highlight a widening regulatory split on psychedelic medicine. While the FDA convened researchers and advocates last week to discuss pathways for legal psychedelic treatments, the DEA is advancing restrictions that could complicate clinical research.
"We have the FDA attempting to move forward a promising new treatment while the DEA is doing everything they can to obstruct its development," said Jack Gorsline, editor of Psychedelic State(s) of America.
The Regulatory Divide
The FDA hearing, held at agency headquarters, brought together researchers, clinicians, and industry representatives to examine how psychedelic drugs might be integrated into mainstream medicine. Discussions centered on clinical trial design, safety protocols, and regulatory frameworks for drugs like psilocybin and MDMA.
But the DEA's scheduling proposals would place additional compounds under the strictest federal drug classification—the same category as heroin and cannabis. Schedule I designation means a substance has no accepted medical use and high abuse potential, making research significantly more difficult and expensive.
The timing has frustrated psychedelic medicine advocates who see parallels to cannabis policy conflicts. For decades, cannabis remained Schedule I even as states legalized medical use and research mounted on therapeutic applications. The DEA only recently proposed moving cannabis to Schedule III.
Research at Risk
Schedule I classification requires researchers to obtain special DEA licenses, maintain enhanced security measures, and navigate extensive paperwork. These barriers have historically limited cannabis research—a pattern the psychedelic research community fears will repeat.
Several clinical trials are currently underway examining psilocybin for depression and PTSD, MDMA for trauma treatment, and other psychedelic applications. Researchers warn that expanded DEA restrictions could slow enrollment, increase costs, and deter institutional participation.
The cannabis industry has watched psychedelic policy development closely. Some cannabis companies have launched psychedelic research divisions, betting that psychedelics will follow a similar path from prohibition to medical acceptance to broader legalization.
What Happens Next
The DEA's scheduling proposals are subject to public comment periods before becoming final. The FDA, meanwhile, continues reviewing clinical trial data for several psychedelic therapies, with decisions on MDMA-assisted therapy expected later this year.
Congress has also taken notice. Several lawmakers have questioned why federal agencies aren't coordinating better on psychedelic policy, particularly when research shows therapeutic potential.
The outcome could shape not just psychedelic medicine but broader drug policy reform. If the FDA approves psychedelic therapies while the DEA maintains strict scheduling, it would create the same regulatory contradiction that has plagued cannabis policy for years.
For now, researchers and companies are caught between two federal agencies moving in opposite directions on the same compounds.
This article is based on original reporting by www.marijuanamoment.net.
